In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neos Therapeutics Inc.

www.neostx.com

Latest From Neos Therapeutics Inc.

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific

Appointments: New CEOs For Lundbeck, Voyager & Neos, CSOs For iTeos & Tilos

Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics, Cevec Pharmaceuticals, Sangamo Therapeutics, Cedilla Therapeutics, Tilos Therepautics and Neos Therapeutics have also appointed new executives and directors.

Appointments Leadership

Pipeline Watch: Topline Readouts With Keytruda, Cosentyx And Zepsyre

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neos Therapeutics Inc.
  • Senior Management
  • Jerry McLaughlin, PhD, CEO
    Richard I Eisenstadt, CFO
    Russ McMahen, SVP, R&D
    Thomas P McDonnell, Chief Commercial Officer
    Margaret Cabano, VP, Operations
    Dorothy Engelking, VP, Reg. Affairs
    Carolyn Sikes, PhD, VP, Clinical Affairs
  • Contact Info
  • Neos Therapeutics Inc.
    Phone: (972) 408-1300
    2940 N. Hwy. 360
    Ste. 400
    Grand Prairie, TX 75050
    USA
UsernamePublicRestriction

Register